Literature DB >> 30542494

Rhein enhances the cytotoxicity of effector lymphocytes in colon cancer under hypoxic conditions.

Xiangfei Yuan1, Wencong Tian1, Yang Hua2, Lijuan Hu1, Jing Yang1, Junmuzi Xie1, Jiacai Hu1, Feng Wang1.   

Abstract

The immunosuppressive tumor microenvironment limits the application of adoptive immunotherapy for solid tumors. Hypoxia is closely associated with the formation of the immunosuppressive tumor microenvironment. Hypoxia-inducible factor-1 (HIF-1) is an oxygen-sensitive transcriptional activator that drives the transcription of several immunosuppressive molecules. In addition, previous studies confirmed that rhein downregulated the expression of HIF-1α, a subunit of HIF-1, in pancreatic cancer cells. The present study established correlations between mRNA expression levels of HIF-1α and six immunosuppressive molecules in colorectal cancer (CRC) tissue samples. This study examined the effect of rhein on the expression levels of HIF-1α and six immunosuppressive molecules in CRC cell lines under hypoxic conditions by western blot analysis and reverse transcription-quantitative polymerase chain reaction. This study demonstrated that rhein downregulated the expression of HIF-1α and immunosuppressive molecules in CRC cells under hypoxic conditions. In addition, the present study analyzed the cytotoxicity of peripheral blood lymphocytes in vitro using a non-toxic cytotoxicity assay. This study demonstrated that in vitro, rhein enhanced the cytotoxicity of effector lymphocytes toward tumor cells under hypoxic conditions, and therefore rhein may be used in combination with effector lymphocytes for the treatment of CRC.

Entities:  

Keywords:  colorectal cancer; effector lymphocyte; hypoxia; hypoxia-inducible factor-1; immunosuppressive tumor microenvironment; rhein

Year:  2018        PMID: 30542494      PMCID: PMC6257589          DOI: 10.3892/etm.2018.6855

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  25 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Emodin Decreases Hepatic Hypoxia-Inducible Factor-1[Formula: see text] by Inhibiting its Biosynthesis.

Authors:  Feifei Ma; Lijuan Hu; Ming Yu; Feng Wang
Journal:  Am J Chin Med       Date:  2016-07-19       Impact factor: 4.667

3.  Hypoxia inducible factor-1 mediates expression of galectin-1: the potential role in migration/invasion of colorectal cancer cells.

Authors:  Xu-Yun Zhao; Ting-Ting Chen; Li Xia; Meng Guo; Ying Xu; Fei Yue; Yi Jiang; Guo-Qiang Chen; Ke-Wen Zhao
Journal:  Carcinogenesis       Date:  2010-06-04       Impact factor: 4.944

4.  Inhibition of HIF-1α enhances anti-tumor effects of dendritic cell-based vaccination in a mouse model of breast cancer.

Authors:  Nasim Kheshtchin; Samaneh Arab; Maryam Ajami; Reza Mirzaei; Mahboubeh Ashourpour; Neda Mousavi; Najmeh Khosravianfar; Farhad Jadidi-Niaragh; Afshin Namdar; Farshid Noorbakhsh; Jamshid Hadjati
Journal:  Cancer Immunol Immunother       Date:  2016-08-06       Impact factor: 6.968

5.  A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.

Authors:  Ivraym B Barsoum; Chelsea A Smallwood; D Robert Siemens; Charles H Graham
Journal:  Cancer Res       Date:  2013-12-13       Impact factor: 12.701

Review 6.  Hypoxia-inducible factors in T lymphocyte differentiation and function. A Review in the Theme: Cellular Responses to Hypoxia.

Authors:  Jin-Hui Tao; Joseph Barbi; Fan Pan
Journal:  Am J Physiol Cell Physiol       Date:  2015-09-09       Impact factor: 4.249

7.  Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa.

Authors:  Eric T Clambey; Eóin N McNamee; Joseph A Westrich; Louise E Glover; Eric L Campbell; Paul Jedlicka; Edwin F de Zoeten; John C Cambier; Kurt R Stenmark; Sean P Colgan; Holger K Eltzschig
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-17       Impact factor: 11.205

Review 8.  The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment.

Authors:  Alexander Greenhough; Helena J M Smartt; Amy E Moore; Heather R Roberts; Ann C Williams; Christos Paraskeva; Abderrahmane Kaidi
Journal:  Carcinogenesis       Date:  2009-01-09       Impact factor: 4.944

9.  Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan.

Authors:  Xiaolong Zhang; Yuanyuan Yang; Leisheng Zhang; Yang Lu; Qing Zhang; Dongmei Fan; Yizhi Zhang; Yanjun Zhang; Zhou Ye; Dongsheng Xiong
Journal:  J Hematol Oncol       Date:  2017-02-23       Impact factor: 17.388

Review 10.  Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects.

Authors:  Yelei Guo; Yao Wang; Weidong Han
Journal:  J Immunol Res       Date:  2016-02-21       Impact factor: 4.818

View more
  4 in total

Review 1.  Evidence for Anticancer Effects of Chinese Medicine Monomers on Colorectal Cancer.

Authors:  Tian-Hao Guo; Yuan-Yuan Li; Sheng-Wei Hong; Qian-Yu Cao; Heng Chen; Yuan Xu; Guo-Liang Dai; Gang Shao
Journal:  Chin J Integr Med       Date:  2022-04-13       Impact factor: 2.626

Review 2.  Therapeutic Emergence of Rhein as a Potential Anticancer Drug: A Review of Its Molecular Targets and Anticancer Properties.

Authors:  Sahu Henamayee; Kishore Banik; Bethsebie Lalduhsaki Sailo; Bano Shabnam; Choudhary Harsha; Satti Srilakshmi; Naidu Vgm; Seung Ho Baek; Kwang Seok Ahn; Ajaikumar B Kunnumakkara
Journal:  Molecules       Date:  2020-05-12       Impact factor: 4.411

Review 3.  Polymer nanoparticle-assisted chemotherapy of pancreatic cancer.

Authors:  Tianqi Su; Bo Yang; Tianren Gao; Tongjun Liu; Jiannan Li
Journal:  Ther Adv Med Oncol       Date:  2020-05-08       Impact factor: 8.168

4.  Rhein Suppresses Colorectal Cancer Cell Growth by Inhibiting the mTOR Pathway In Vitro and In Vivo.

Authors:  Haibo Zhang; Jun-Koo Yi; Hai Huang; Song Park; Sijun Park; Wookbong Kwon; Eungyung Kim; Soyoung Jang; Si-Yong Kim; Seong-Kyoon Choi; Sung-Hyun Kim; Kangdong Liu; Zigang Dong; Zae Young Ryoo; Myoung Ok Kim
Journal:  Cancers (Basel)       Date:  2021-04-30       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.